---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-26-000007"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:22:36.082247+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer

## Summary
- Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.
- Casdatifan 100mg QD in late-line ccRCC: confirmed ORR 45.2%, median PFS 15.1 months (Jan 30, 2026 cut).
- Full-year 2026 GAAP revenue guidance $45-55M; R&D expenses expected to decrease meaningfully.
- Phase 3 PEAK-1 (casdatifan + cabozantinib) enrolling globally; 1L Phase 3 planned by end 2026.
- First inflammation program (oral MRGPRX2 antagonist) to enter clinic in 2026; oral TNF inhibitor in late 2026/early 2027.

## SEC filing metadata
- accession: 0001724521-26-000007
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/0001724521-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/rcus-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-26-000007
- JSON: https://secwatch.observer/filing/0001724521-26-000007.json
- Plain text: https://secwatch.observer/filing/0001724521-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.